Incyte earnings were $403.4M for the trailing 12 months ending Sep 30, 2026, with -65.4% growth year over year. The latest INCY earnings report on Sep 30, 2026 announced Q3 2026 earnings of -$784.8M, down 234% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, INCY reported annual earnings of $1.3B, with 3,845% growth.
INCY past earnings growth
How has INCY's earnings growth performed historically?
On INCY's earnings call on Oct 29, 2026, Incyte (NASDAQ: INCY) reported Q3 2026 earnings per share (EPS) of -$3.86, up 277.88% year over year. Total INCY earnings for the quarter were -$784.80 million. In the same quarter last year, Incyte's earnings per share (EPS) was $2.17.
As of the last Incyte earnings report, Incyte is currently profitable. Incyte's net profit (also called net income) for the twelve months ending Sep 30, 2026 was $403.41 million, a 66.06% decrease year over year.
What was INCY's earnings growth in the past year?
As of Incyte's earnings date in Oct 29, 2026, Incyte's earnings has grown -65.4% year over year. This is 107.49 percentage points lower than the US Biotechnology industry earnings growth rate of 42.1%. INCY earnings in the past year totalled $403.41 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.